Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Institute of Anesthesiology and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Immunol. 2021 Jun 2;12:651545. doi: 10.3389/fimmu.2021.651545. eCollection 2021.
COVID-19 is an acute, complex disorder that was caused by a new β-coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Based on current reports, it was surprising that the characteristics of many patients with COVID-19, who fulfil the Berlin criteria for acute respiratory distress syndrome (ARDS), are not always like those of patients with typical ARDS and can change over time. While the mechanisms of COVID-19-related respiratory dysfunction in COVID-19 have not yet been fully elucidated, pulmonary microvascular thrombosis is speculated to be involved. Considering that thrombosis is highly related to other inflammatory lung diseases, immunothrombosis, a two-way process that links coagulation and inflammation, seems to be involved in the pathophysiology of COVID-19, including respiratory dysfunction. Thus, the current manuscript will describe the proinflammatory milieu in COVID-19, summarize current evidence of thrombosis in COVID-19, and discuss possible interactions between these two.
COVID-19 是一种由新型β冠状病毒——严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）引起的急性、复杂疾病。根据目前的报告，令人惊讶的是，许多符合急性呼吸窘迫综合征（ARDS）柏林标准的 COVID-19 患者的特征并不总是与典型 ARDS 患者的特征一样，并且会随时间而变化。虽然 COVID-19 相关呼吸功能障碍的机制尚未完全阐明，但推测肺微血管血栓形成与此有关。鉴于血栓与其他炎症性肺病高度相关，免疫血栓形成（一种连接凝血和炎症的双向过程）似乎与 COVID-19 的病理生理学，包括呼吸功能障碍有关。因此，本手稿将描述 COVID-19 中的促炎环境，总结 COVID-19 中血栓形成的现有证据，并讨论这两者之间可能的相互作用。
